ArticleDigestive diseases and sciences2025
Alterations in Gut Microbiota and Stool Properties Following Treatment with Potassium-Competitive Acid Blocker and Proton Pump Inhibitor.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProton pump inhibitors (PPIs) and potassium-competitive acid blockers (PCABs) have been reported to alter the gut microbiota. However, the relationship between these alterations and stool properties remains unclear. This study aimed to examine changes in the gut microbiota, stool consistency, and subjective symptoms related to defecation after antacid treatment.
methodsPatients who received PPI or PCAB for 6 weeks following endoscopic submucosal dissection for upper gastrointestinal cancers between August 2017 and June 2020 were recruited. Fecal samples were analyzed using amplicon sequencing. Stool consistency and defecation-related symptoms were evaluated using the Bristol Stool Scale (BSS) and Constipation Assessment Scale, respectively.
resultsForty participants (PPI group, n = 20; PCAB group, n = 20) were enrolled in this study. The BSS was significantly lower after PCAB treatment (p = 0.044). The Chao-1 index significantly increased after PCAB treatment (p < 0.01). The PPI group had increased Streptococcus and Veillonella after treatment, whereas the PCAB group had significantly increased Lactobacillus and Akkermansia, in addition to Streptococcus. The genus Blautia was significantly reduced in the PCAB group following treatment. The group with reduced BSS had significantly lower abundance of Bifidobacterium, Faecalibacterium, and Coprococcus before PCAB treatment. In patients with constipation symptoms, Streptococcus and Lactobacillus significantly increased after PCAB treatment.
conclusionsThe incidence of constipation increased following PCAB treatment. The observed alterations in specific oral commensal bacteria and butylate-producing bacteria differed between the PCAB and PPI groups and may have contributed to the development of abnormal stool properties.
Indexed as
Identifiers
40705251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.